Hangzhou Zhongmei Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HANGZHOU ZHONGMEI, and what generic and branded alternatives to HANGZHOU ZHONGMEI drugs are available?
HANGZHOU ZHONGMEI has five approved drugs.
Drugs and US Patents for Hangzhou Zhongmei
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hangzhou Zhongmei | ACARBOSE | acarbose | TABLET;ORAL | 213821-001 | Aug 18, 2020 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Hangzhou Zhongmei | DAPTOMYCIN | daptomycin | POWDER;INTRAVENOUS | 215215-001 | Nov 26, 2021 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Hangzhou Zhongmei | FONDAPARINUX SODIUM | fondaparinux sodium | INJECTABLE;SUBCUTANEOUS | 216493-002 | Aug 19, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.